Final clinical trials for a coronavirus vaccine, developed by Astrazeneca and Oxford University, have been put on hold after a participant had a suspected adverse reaction in the UK.
Astrazeneca described it as a “routine” pause in the case of “an unexplained illness”.
The Astrazeneca-Oxford University Vaccine is seen as a strong contender among dozens being developed globally.
Hopes have been high that the vaccine might be one of the first to come on the market, following successful phase 1 and 2 testing.
Its move to phase 3 testing in recent weeks has involved some 30,000 participants in the US as well as in the UK, Brazil and South Africa.
Phase 3 trials in vaccines often involve thousands of participants and can last several years. The world health organization (who) says nearly 180 vaccine candidates are being tested around the world but none has yet completed clinical trials.